
usd jan pm et
summari compani develop novel antibodi therapeut target varieti rare sever
diseas state includ autoimmun disord inflamm cancer
price-to-earnings oper ep
depend sale drug
make compani vulner weak sale
obsolesc major product howev
promis pipelin low level debt posit
cash flow recent year bode well
compani abil remain go concern
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
dec pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
target price reflect
multipl ep
estim ep vs
estim lower
ep
commenc ep sale
grew yoy billion
expect full-year sale soliri
ultomiri combin million
million higher expect
expect substanti increas non-gaap
spend million support pipelin
progress aim commerci
launch five
ultomiri variou indic deliveri
look light rel consensu expect
load dose dynam patient
switch ultomiri benefit revenu
addit manag highlight
ad new patent soliri
 provid addit patent protect
 huang cfa
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
independ chairman
board
commerci global
corpor overview develop novel antibodi therapeut target
varieti sever disord includ autoimmun cardiovascular diseas inflamm cancer
global leader complement inhibit first market product soliri eculizumab
first therapi approv treatment patient paroxysm nocturn hemoglobinuria pnh
soliri design inhibit specif aspect complement compon immun system
therebi treat inflamm associ chronic hematolog neurolog disord transplant
reject autoimmun disord
soliri compris alxn product revenu soliri human monoclon antibodi
complement inhibitor block cleavag compon complement cascad
prevent final stage complement activ soliri approv treatment pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi gmg europ japan
sever countri
latest commerci market drug ultomiri formerli approv decemb
fda treatment patient pnh announc top-lin phase
switch data ultomiri show patient paroxysm nocturn
hemoglobinuria pnh effect safe switch treatment soliri everi week treatment
ultomiri everi week ultomiri safeti profil consist soliri total data
favor ultomiri soliri aim convert pnh patient soliri ultomiri end
also work phase clinic trial ultomiri ahu gmg diseas
current address alxn drug soliri
also market strensiq hypophosphatasia kanuma lyosom acid lipas defici
lal-d decemb three phase clinic program one phase ii program
impact major develop octob announc intent acquir achillion
achn initi net payment approxim million conting valu
right per share fda approv drug danicopan per share phase
trial initi clinic candid assum roadblock think
certainli could especi around ftc approv expect acquisit close
think deal make lot sens mitig potenti competit
achn work treat paroxysm nocturn hemoglobinuria pnh deal also
complement alxn core expertis achn advanc candid danicopan phase studi
pnh patient sub-optimal respons soliri ultra-rar kidney diseas patient
august patent trial appeal board ptab announc would review claim
relat three patent alxn key drug soliri request neg outcom
ptab review could expos soliri biosimilar competit earlier expect
complet acquisit syntimmun inc clinical-stag biotechnolog compani
develop antibodi therapi target neonat fc receptor fcrn million
potenti addit milestone-depend payment million lead candid
acquisit monoclon antibodi inhibit interact fcrn
immunoglobulin igg igg immun complex studi phase trial
treatment igg-medi autoimmun diseas
may acquir wilson therapeut ab total consider million result
acquisit ad pipelin candid highli innov drug candid
current earli stage phase clinic trial treatment patient wilson
diseas pipelin
prior last major acquisit june acquir synageva biopharma
geva nr billion consist cash share
geva share geva kanuma treatment lysosom acid lipas defici orphan drug statu
us eu
financi trend alxn sale increas year-over-year billion billion
reflect five-year compound annual growth rate compound-annual-growth-rate compani ep expand
year-over-year reflect five-year compound-annual-growth-rate given compani low debt level
decemb posit free cash flow past five fiscal year think
well-posit continu fund research develop effort even extern
financ becom significantli limit decemb leverag ratio net debt
trailing-twelve-month ebitda annual million
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
defens sub-industri expect
see ramp-up new drug sale continu
develop mani new innov therapi
declin preval patent
expir anticip
novel fda drug approv
year-over-year record level
partli due govern shutdown earli
year fda approv novel drug
shatter previou record sinc
novel approv set new
drug typic take least five year
reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
although deal count
biopharmaceut lower
past decad total deal valu
transact anticip largest
amount sinc accord
evaluatepharma total deal valu driven
coupl mega-d bristol-mey
squibb acquisit celgen
abbvi acquisit botox
manufactur allergan decemb
biotech industri debt level valuat
remain low rel histor level
rel industri lead us
believ continu
favor environ howev
think difficult beat total
deal valu transact
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen regulatori
legisl front neg impact
profit biotech firm believ
littl continu achiev politician
address rise health care cost
especi around drug price
impeach proceed novemb
presidenti candid may continu bring
drug price key issu anticip
stock near term think
legisl initi relat drug fall
focu howev presidenti
elect expect drug legisl becom
key area focu legisl
exclus period origin biolog
drug face competit form
biosimilar also typic
manufactur biopharmaceut firm
howev brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
increas driven ralli
compar rise valu
 composit index
declin
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
share trade sharpli today news patent
trial appeal board ptab review claim relat three patent
key drug soliri compris product revenu previous
highlight signific revenu concentr soliri signific
risk neg outcom ptab review could expos soliri biosimilar
competit howev alreadi expect
soliri sale could face competit pressur view
success execut strategi mitig competit pressur
strategi primarili involv convert soliri patient newer
conveni drug ultomiri expect ptab review take year
pm et cfra maintain buy opinion share
lower target base multipl
ep estim ep vs
exceed consensu estim rais ep
ep sale billion
reflect yoy growth driven increas volum off-set
foreign currenc headwind price headwind price headwind
larg relat on-going disput canadian drug price
board begin week paroxysm nocturn
hemoglobinuria pnh patient convert treatment soliri
ultomiri last quarter septemb expect
decis valid two patent relat soliri europ
even outcom neg biosimilar competit soliri least
three year away strategi make ultomiri standard care
analyst research note compani news
pm et cfra keep strong buy opinion share alexion
lower target price
reflect multipl ep estim
ep vs estim lower ep
commenc ep sale grew
yoy billion expect full-year sale soliri
ultomiri combin million million higher expect
expect substanti increas non-gaap spend
million support pipelin progress aim commerci launch
five ultomiri variou indic
deliveri method revenu growth guidanc look light rel
consensu expect load dose dynam patient switch
ultomiri benefit revenu addit manag
highlight ad new patent soliri provid
addit patent protect /kevin huang cfa
pm et cfra keep strong buy opinion share alexion
top-line phase data pozelimab patient paroxysm nocturn
hemoglobinuria pnh diseas treat drug ultomiri
soliri patient trial total receiv weekli dose regimen
pozelimab week brought patient previously-elev lactat
dehydrogenas ldg level normal rang without seriou advers event
current view pozelimab seriou threat valuat
alreadi well way establish ultomiri
standard care anticip competit next year
time pozelimab could make market believ
convert almost patient soliri ultomiri
also believ consensu estim alreadi factor competit headwind
stronger anticip /kevin huang cfa
pm et cfra lift opinion share
strong buy buy maintain target
reflect multipl ep estim
ep vs exceed estim lift ep
ep sale grew
yoy billion driven increas volum slightli off-set
price headwind much less sever last quarter price
headwind begin week paroxysm nocturn
hemoglobinuria pnh patient convert treatment soliri
ultomiri juli april convers progress
ahead origin expect engag elev level
busi develop activ recent evidenc deal announc
past two month stealth biotherapeut
expect continu alloc resourc
pm et cfra maintain buy opinion share alexion
pharmaceut inc today announc intent
acquir achn initi net payment
approxim million conting valu right per share
fda approv drug danicopan per share phase
trial initi clinic candid assum
roadblock think certainli could especi around ftc
approv expect acquisit close think
deal make lot sens mitig potenti
competit achn work treat paroxysm nocturn hemoglobinuria
 pnh deal also complement core expertis achn
advanc candid danicopan phase studi pnh patient
sub-optimal respons soliri ultra-rar kidney diseas /kevin
et cfra keep buy opinion share
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
